Corvus Pharmaceuticals Names Jason V. Coloma to Newly Created Post of Chief Business Officer
June 29 2016 - 8:30AM
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of novel immuno-oncology therapies, today
announced it has named former Roche/Genentech Vice President,
Global Head of Roche Oncology Business Development, Jason, V.
Coloma, Ph.D., to the newly created post of Senior Vice President
and Chief Business Officer.
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/d0cf7156-361a-4d25-bed1-45ad26fe37ca
Dr. Coloma began his career as a research scientist in
infectious diseases at the University of California, San Francisco
(UCSF). In 2007, he joined L.E.K. Consulting, as a strategy
consultant for pharma / biotechnology corporations and private
equity firms developing partnerships, mergers & acquisitions,
and market expansion opportunities primarily in the oncology market
for his clients. For the last 8+ years, Dr. Coloma has worked
in senior leadership positions related to business and commercial
development at Roche Diagnostics and then Roche/Genentech. Most
recently, he led a team of business development professionals,
business analysts, and competitive intelligence experts charged
with augmenting Roche’s drug discovery and oncology business
efforts where he facilitated the closing of a number of deals
including Foundation Medicine, Blueprint Medicines, sQz
Therapeutics, Tensha Therapeutics, C4 Therapeutics, and Pieris
Pharmaceuticals. He also oversaw the creation of the
immuno-oncology clinical partnership function at Genentech that
completed several transactions including those with Celgene,
J&J, Bayer, Syndax, Kite, Amgen, and Corvus Pharmaceuticals.
Dr. Coloma earned his B.S. in molecular biology from the University
of San Francisco. He received his M.P.H./Ph.D. in Infectious
Diseases and Immunity from the University of California, Berkeley
and his M.B.A. from the Tuck School of Business at Dartmouth.
“Jason’s experience across large pharma and development stage
biotech, particularly in oncology, means he brings to Corvus a deep
understanding of the opportunities and strategy necessary to build
a successful portfolio of cancer products,” said Richard A. Miller,
M.D., an oncologist and co-founder, president and chief executive
officer of Corvus. “Dr. Coloma is ideally suited to help us
commercialize our current product candidates and to in-license or
acquire additional product opportunities.”
“This is an exciting time to be working in the field of
immuno-oncology,” said Dr. Coloma. “I am particularly pleased
to become part of the Corvus team of accomplished and talented
clinical and scientific experts who are working on cutting edge
approaches to immuno-oncology and helping deliver innovative
therapies to patients.”
About Corvus Pharmaceuticals Corvus
Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on the development and commercialization of small molecule
and antibody agents that target the immune system to treat patients
with cancer. These agents block or modify crucial immune
checkpoints and reprogram immune T-cells. Corvus’ lead product,
CPI-444 is a checkpoint inhibitor that is designed to disable a
tumor’s ability to subvert attack by the immune system by
inhibiting adenosine in the tumor microenvironment. CPI-444 is a
small molecule that is taken orally. CPI-444 is being evaluated in
a multicenter Phase 1/1b clinical trial in patients with various
solid tumors. This successive expansion cohort trial is examining
the activity of CPI-444 both as a single agent and in combination
with TECENTRIQ™ (atezolizumab), Genentech's investigational cancer
immunotherapy. TECENTRIQ™ is a fully humanized monoclonal antibody
targeting protein programmed cell death ligand 1 (PD-L1). Corvus is
conducting the trial with Genentech, a member of the Roche Group,
under a clinical trial collaboration the two companies entered into
in October 2015. For more information, visit
www.corvuspharma.com.
Investor Contact:
Leiv Lea
Chief Financial Officer
LLea@corvuspharma.com
650-900-4522
Media Contact:
Julie Normart, W2O Group
415-946-1087
jnormart@w2ogroup.com
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Apr 2023 to Apr 2024